Ezrin expression is related to poor prognosis in FIGO stage I endometrioid carcinomas

被引:51
作者
Köbel, M
Langhammer, T
Hüttelmaier, S
Schmitt, WD
Kriese, K
Dittmer, R
Strauss, HG
Thomssen, C
Hauptmann, S
机构
[1] Univ Halle Wittenberg, Inst Pathol, D-06097 Halle, Germany
[2] Univ Halle Wittenberg, Dept Gynecol, D-06097 Halle, Germany
[3] Univ Halle Wittenberg, ZAMED, Dept Med, D-06097 Halle, Germany
关键词
ezrin; osteopontin; expression; endometrioid carcinoma; FIGO I; prognosis;
D O I
10.1038/modpathol.3800567
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
As a cortical cytoskeletal protein, ezrin adapts the cytoplasmic tail of CD44 to the actin-based cytoskeleton and is functionally involved in migration and adhesion that are prerequisites for metastasis. To assess the importance of ezrin and its associated protein osteopontin for the progression of endometrioid carcinoma in FIGO stage I, we analyzed paraffin-embedded tissue from 164 patients by immunohistochemistry and correlated these data with clinicopathological parameters. Ezrin was expressed in normal proliferating endometrial glands, as was confirmed by quantitative PCR and immunohistochemistry. In endometrioid carcinoma, enhanced ezrin expression correlated with a reduced overall survival in univariate analysis (P=0.041). In contrast, no significant correlation was found for osteopontin. In multivariate survival analysis, among FIGO grade 3 and age, ezrin was still found to be an independent risk factor (relative risk 2.2, confidence interval 1.0-5.4, P = 0.047). Hence, elevated ezrin expression is a new independent prognostic marker in FIGO stage I endometrioid carcinoma, and thus provides further evidence for an important role of ezrin in tumor progression.
引用
收藏
页码:581 / 587
页数:7
相关论文
共 19 条
[1]   High levels of ezrin expressed by human pancreatic adenocarcinoma cell lines with high metastatic potential [J].
Akisawa, N ;
Nishimori, I ;
Iwamura, T ;
Onishi, S ;
Hollingsworth, MA .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 258 (02) :395-400
[2]   Long-term survival of cancer patients in Germany achieved by the beginning of the third millenium [J].
Brenner, H ;
Stegmaier, C ;
Ziegler, H .
ANNALS OF ONCOLOGY, 2005, 16 (06) :981-986
[3]   Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies [J].
Coppola, D ;
Szabo, M ;
Boulware, D ;
Muraca, P ;
Alsarraj, M ;
Chambers, AF ;
Yeatman, TJ .
CLINICAL CANCER RESEARCH, 2004, 10 (01) :184-190
[4]   Ezrin ... a metastatic detERMinant? [J].
Curto, M ;
McClatchey, AI .
CANCER CELL, 2004, 5 (02) :113-114
[5]   The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells [J].
Elliott, BE ;
Meens, JA ;
SenGupta, SK ;
Louvard, D ;
Arpin, M .
BREAST CANCER RESEARCH, 2005, 7 (03) :R365-R373
[6]   Ezrin, a plasma membrane-microfilament linker, signals cell survival through the phosphatidylinositol 3-kinase/Akt pathway [J].
Gautreau, A ;
Poullet, PR ;
Louvard, D ;
Arpin, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (13) :7300-7305
[7]   Ezrin in primary cutaneous melanoma [J].
Ilmonen, S ;
Vaheri, A ;
Asko-Seljavaara, S ;
Carpen, O .
MODERN PATHOLOGY, 2005, 18 (04) :503-510
[8]   Cancer statistics, 2005 [J].
Jemal, A ;
Murray, T ;
Ward, E ;
Samuels, A ;
Tiwari, RC ;
Ghafoor, A ;
Feuer, EJ ;
Thun, MJ .
CA-A CANCER JOURNAL FOR CLINICIANS, 2005, 55 (01) :10-30
[9]   The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis [J].
Khanna C. ;
Wan X. ;
Bose S. ;
Cassaday R. ;
Olomu O. ;
Mendoza A. ;
Yeung C. ;
Gorlick R. ;
Hewitt S.M. ;
Helman L.J. .
Nature Medicine, 2004, 10 (2) :182-186
[10]   Osteopontin as a potential diagnostic biomarker for ovarian cancer [J].
Kim, JH ;
Skates, SJ ;
Uede, T ;
Wong, KK ;
Schorge, JO ;
Feltmate, CM ;
Berkowitz, RS ;
Cramer, DW ;
Mok, SC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (13) :1671-1679